Skip to main content
. 2023 Aug 2;21(8):e3002227. doi: 10.1371/journal.pbio.3002227

Fig 7. MAPK4 promotes cancer cell resistance to PI3K and PDK1 co-blockade.

Fig 7

(A) Proliferation assays, (B) plate colony formation assays, and (C) soft-agar assays on the engineered SUM159 and HCC1806 cells with 0.5 μg/ml Dox-induced overexpression of MAPK4 (iMAPK4) or control (iCtrl). The cells were also treated with DMSO control, PDK1 inhibitor GSK2334470 (2 μm), PI3K inhibitor Alpelisib (2 μm), or both inhibitors. Scale bar: 500 μm. Quantification data as means ± SD. P values by two-way ANOVA followed by Sidak’s multiple comparisons. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. ns, not significant. Data are representative of at least 3 independent experiments. The numerical values underlying the figures can be found in S1 Data. MAPK4, mitogen-activated protein kinase 4; PDK1, phosphoinositide-dependent kinase-1.